Real-world effectiveness of nab-paclitaxel plus carboplatin as first-line therapy for patients with advanced NSCLC: Results of the second interim analysis of the NEPTUN study. 13. Juli 2020 Dechow T, Riera-Knorrenschild J, Hackanson B, Fischer von Weikersthal L, Schulz H, Chiabudini M, Timm B, Zerbes R, Potthoff K, 2020. J Clin Oncol 38: 2020 (suppl; abstr e21611) doi: 10.1200/JCO.2020.38.15_suppl.e21611 Dynamics in the choice of treatment for patients with Multiple Myeloma – Results from the MYRIAM registry. Engelhardt, M., Knauf, W., Lipke, J., Reiser, M., Dörfel, S., Kortüm, M., Schlag, R., von der Heyde, E., La Rosée, P., Pfannes, R., Lamberti, C.,… Weiterlesen REFLECT real-world evidence (RWE) prospective study update: Efficacy and safety results of Sandoz biosimilar rituximab (SDZ-RTX) for the treatment of diffuse large B-cell lymphoma (DLBCL). Welslau M, Marschner N, Otremba B, Topaly J, Bittencourt da Silva L, 2020. J Clin Oncol 38 no. 15_suppl (May 20, 2020) 8060-8060. DOI:… Weiterlesen